Fibromyalgia comorbid with anxiety disorders and depression: Combined medical and psychological treatment

Current Pain and Headache Reports

Volumn 17, Issue 9, 2013, Pages

  Bernik, Marcio ^a   Sampaio, Thiago P A ^a   Gandarela, Lucas ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antidepressive agents; Anxiety disorders; Chronic pain; Cognitive behavioral therapy; Depressive disorders; Drug therapy; Duloxetine; Fibromyalgia; Mental disorders; Milnacipran; Pregabalin; Tricyclic

Indexed keywords

AGOMELATINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DESVENLAFAXINE; DULOXETINE; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; IMIPRAMINE; MILNACIPRAN; NORTRIPTYLINE; PAROXETINE; PLACEBO; PREGABALIN; QUETIAPINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADD ON THERAPY; AGORAPHOBIA; ALTERNATIVE MEDICINE; ANALGESIC ACTIVITY; ANXIETY DISORDER; ARTICLE; CHRONIC PAIN; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DIABETIC NEUROPATHY; DISEASE PREDISPOSITION; DRUG APPROVAL; DRUG CHOICE; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; FATIGUE; FIBROMYALGIA; GENERALIZED ANXIETY DISORDER; HUMAN; HYPERSOMNIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; KINESIOTHERAPY; LIFE STRESS; LIFESTYLE MODIFICATION; MAJOR DEPRESSION; MANIPULATIVE MEDICINE; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PANIC; PATHOGENESIS; POSTTRAUMATIC STRESS DISORDER; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOCIAL PHOBIA; ANXIETY DISORDERS; PSYCHOLOGY; PSYCHOLOGICAL ASPECT; REVIEW;

ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; COGNITIVE THERAPY; DEPRESSION; FIBROMYALGIA; HUMANS;

EID: 84880666022     PISSN: 15313433     EISSN: 15343081     Source Type: Journal    
DOI: 10.1007/s11916-013-0358-3     Document Type: Article

References (89)

1. Van Houdenhove B, Luyten P. Beyond dualism: the role of life stress in chronic pain. Pain. 2005;113:238-9. (Pubitemid 40038466)
2. Gracely RH, Petzke F, Wolf JM, et al. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 2002;46:1333-43. (Pubitemid 34525843)
3. Hamilton NA, Atchley RA, Karlson CW, et al. The role of sleep and attention in the etiology and maintenance of fibromyalgia. Cogn Ther Res. 2012;36:81-93.
4. Van Houdenhove B, Egle UT. Fibromyalgia: a stress disorder? Piecing the biopsychosocial puzzle together. Psychoter Psychosom. 2004;73:267-75. (Pubitemid 39060995)
5. Konnopka A, Schaefert R, Heinrich S, et al. Economics of medically unexplained symptoms: a systematic review of the literature. Psychother Psychosom. 2012;81:265-75.
6. Andersen NL, Eplov LF, Andersen JT, et al. Health care use by patients with somatoform disorders: a register-based follow-up study. Psychosomatics. 2013;54:132-41.
7. Knight T, Schaefer C, Chandran A, et al. Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States. Clinicoecon Outcomes Res. 2013;5:171-80.
8. Warren JW, Clauw DJ. Functional somatic syndromes: sensitivities and specificities of self-reports of physician diagnosis. Psychosom Med. 2012;74:891-5.
9. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010;62:600-10.
10. Vincent A, Lahr BD, Wolfe F, et al. Prevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester epidemiology project. Arthritis Care Res. 2013;65:786-92.
11. Arnold LM, Hudson JI, Keck PE, et al. Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry. 2006;67:1219-25. (Pubitemid 44439693)
12. Dickens C, McGowan L, Clark-Carter D, et al. Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom Med. 2002;64:52-60. (Pubitemid 34137399)
13. Haviland MG, Banta JE, Przekop P. Fibromyalgia: prevalence, course, and co-morbidities in hospitalized patients in the United States, 1999-2007. Clin Exp Rheumatol. 2011;29:S79-87.
14. Giesecke T, Williams DA, Harris RE, et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum. 2003;48:2916-22. (Pubitemid 37280621)
15. Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry. 2003;60:39-47. (Pubitemid 36070863)
16. Corruble E, Guelfi JD. Pain complaints in depressed inpatients. Psychopathology. 2000;33:307-9.
17. Fassbender K, Samborsky W, Kellner M, et al. Tender points, depressive and functional symptoms: comparison between fibromyalgia and major depression. Clin Rheumatol. 1997;16:76-9. (Pubitemid 27101296)
18. Kuchinad A, Schweinhardt P, Seminowicz DA, et al. Accelerated brain gray matter loss in fibromyalgia patients: premature aging of brain? J Neurosci. 2007;27:4004-7. (Pubitemid 46597143)
19. Vilarreal G, Hamilton DA, Petropoulos H, et al. Reduced hippocampal volume and total white matter in post-traumatic stress disorder. Biol Psychiatry. 2002;52:119-25. (Pubitemid 34756557)
20. Hsu MC, Harris RE, Sundgren PC, et al. No consistent difference in gray matter volume between individuals with fibromyalgia and age-matched healthy subjects when controlling for affective disorder. Pain. 2009;143:262-7.
21. Giesecke T, Gracely RH, Williams DA, et al. The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum. 2005;52:1577-84. (Pubitemid 40663950)
22. Hudson JI, Hudson MS, Pliner LF, et al. Fibromyalgia and major affective disorder: a controlled phenomenology and family history study. Am J Psychiatry. 1985;142:441-6. (Pubitemid 15108206)
23. Arnold LM, Hudson J, Hess EV, et al. Family study of fibromyalgia. Arthritis Rheum. 2004;50:944-52. (Pubitemid 38326195)
24. Ablin JN, Buskila D, Sarzi-Puttini P. The genetics of fibromyalgia syndrome. Pharmacogenomics. 2007;8:67-74. (Pubitemid 46157758)
25. Robinson OJ, Overstreet C, Allen PS, et al. The role of serotonin in the neurocircuitry of negative affective bias: serotonergic modulation of the dorsal medial prefrontal-amygdala "aversive amplification" circuit. Neuroimage. 2013. [Epub ahead of print].
26. •• Smith HS, Harris R, Clauwn D. Fibromyalgia: an afferent processing disorder leading to a complex pain generalized syndrome. Pain Phys. 2011;14:E217-45. This study provides an extensive review on the CNS pathophysiology of fibromyalgia and the mechanisms of action of drugs used in its treatment.
27. Mysliwiec V, McGraw L, Pierce R, et al. Sleep disorders and associated medical comorbidities in active duty military personnel. Sleep. 2013;36:167-74.
28. Yokogawa F, Kiuchi Y, Ishikawa Y, et al. An investigation of monoamine receptors involved in antinociceptive effects of antidepressants. Anesth Analg. 2002;95:163-8. (Pubitemid 34705572)
29. Griep EN, Boersma JW, de Kloet ER. Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome. J Rheumatol. 1993;20:469-74. (Pubitemid 23102470)
30. Graeff FG. Bases biológicas do transtorno de estresse pós-traumático. Rev Bras Psiquiatr. 2003;25(Supl I):21-4. (Pubitemid 36876456)
31. Bohn D, Bernardy K, Wolfe F, et al. The association among child maltreatment, somatic symptoms intensity, depression, and somatoform dissociative symptoms in patients with fibromyalgia syndrome? A single-center cohort study. J Trauma Dissociation. 2013;14:342-58.
32. Lucini D, Pagani M. From stress to functional syndromes: an internist's point of view. Eur J Intern Med. 2012;23:295-301.
33. Gonzalez B, Baptista TM, Branco JC, et al. Fibromyalgia: antecedent life events, disability, and causal attribution. Psychol Health Med. 2013. [Epub ahead of print].
34. Masquelier E, Scaillet N, Luminet O, et al. What's about overactive lifestyle in fibromyalgia and chronic fatigue syndrome. Rev Med Suisse. 2011;7(1421-2):1424-5.
35. Fontaine KR, Conn L, Clauw DJ. Effects of lifestyle physical activity on perceived symptoms and physical function in adults with fibromyalgia: results of a randomized trial. Arthritis Res Ther. 2010;12:55. Available at: http://arthritis-research.com/content/12/2/R55. Accessed May 2013.
36. Alok R, Das SK, Agarwal GG, et al. Relationship of severity of depression, anxiety and stress with severity of fibromyalgia. Clin Exp Rheumatol. 2011;29(6 Suppl 69):S70-2.
37. Kurtze N, Gundersen KT, Svebak S. Quality of life, functional disability and lifestyle among subgroups of fibromyalgia patients: the significance of anxiety and depression. Br J Med Psychol. 1999;72:471-84. (Pubitemid 30018991)
38. Thieme K, Turk DC. Cognitive-behavioural and operant-behavioral therapy for people with fibromyalgia. Reumatismo. 2012;64:275-85.
39. Thieme K, Spies C, Sinha P, et al. Predictors of pain behaviors in fibromyalgia syndrome. Arthritis Rheum. 2005;53:343-50. (Pubitemid 40799871)
40. Van Koulil S, Kraaimaat FW, van Lankeveld W, et al. Screening for pain-persistence and pain-avoidance patterns in fibromyalgia. Intern J Behav Med. 2008;15:211-20.
41. Van Koulil S, Kraaimaat FW, van Lankeveld W, et al. Cognitive-behavioral mechanisms in a pain-avoidance and a pain-persistence treatment for high-risk fibromyalgia patients. Arthritis Care Res. 2011;63:800-7.
42. Van Houdenhove B, Luyten P. Customizing treatment of chronic fatigue syndrome and fibromyalgia: the role of perpetuating factors. Psychosomatics. 2008;49:470-7.
43. Salmon P. The potentially somatizing effect of clinical consultation. CNS Spectr. 2006;11:190-200.
44. • Häuser W, Thieme K, Turk DC. Guidelines on the management of fibromyalgia syndrome -a systematic review. Eur J Pain. 2010;14:5-10. There are many different guidelines for the treatment of fibromyalgia. In this study, the authors compare 3 important guidelines, highlighting similarities and differences in their recommendations.
45. Pergolizzi Jr JV, Raffa RB, Taylor Jr R, et al. A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain. Pain Pract. 2013;13:239-52.
46. Arnold LM, Zhang S, Pangallo BA. Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clin J Pain. 2012;28:775-81.
47. Goldenberg DL, Clauwn DJ, Palmer RH, et al. Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. Pain Med. 2010;11:180-94.
48. Nakagawa A, Watanabe N, Omori IM, et al. Milnacipran vs other antidepressive agents for depression. Cochrane Database Syst Rev. 2009;3:CD006529. doi: 10.1002/14651858.CD006529.pub2.
49. Häuser W, Bernardy K, Uçeyler N, et al. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA. 2009;301:198-2009.
50. Wensel TM, Powe KW, Cates ME. Pregabalin for the treatment of generalized anxiety disorder. Ann Pharmacother. 2012;46:424-9.
51. Häuser W, Urrútia G, Tort S, et al. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database of Syst Rev. 2013;1:CD010292. doi: 10.1002/14651858.CD010292.
52. Arnold LM, Chatamra K, Hirsch I, et al. Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8-week, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2010;32:1618-32.
53. Mariutto EN, Stanford SB, Kashikar-Zuck S, et al. An exploratory, open trial of fluoxetine treatment of juvenile fibromyalgia. J Clin Psychopharmacol. 2012;32:293-5.
54. Stein DJ, Bandelow B, Merideth C, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder: an analysis of pooled data from 3 8-week placebo-controlled studies. Hum Psychopharmacol. 2011;26:614-28.
55. Hidalgo J, Rico-Villademoros F, Calandre EP. An open-label study of quetiapine in the treatment of fibromyalgia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:71-7. (Pubitemid 44959248)
56. Potvin S, Morin M, Cloutier C, et al. Add-on treatment of quetiapine for fibromyalgia: a pilot, randomized, double-blind, placebo-controlled 12-week trial. J Clin Psychopharmacol. 2012;32:684-7.
57. Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28:561-6.
58. Miotto K, Kaufman A, Kong A, et al. Managing co-occurring substance use and pain disorders. Psychiatr Clin North Am. 2012;35:393-409.
59. • Painter JT, Crofford LJ. Chronic opioid use in fibromyalgia syndrome: a clinical review. J Clin Rheumatol. 2013;19:72-7. This study warns for the increases in chronic daily opioid use in fibromyalgia and the risks it poses to aggravating the deficient pain suppression mechanism found in these patients.
60. Wehr T, Goodwin F. Rapid cycling in manic depression induced by tricyclic antidepressants. Arch Gen Psychiatry. 1979;36:555-9. (Pubitemid 9201187)
61. Thase ME. Antidepressants and rapid-cycling bipolar II disorder: dogma, definitions and deconstructing discrepant data. BJP. 2013;202:251-2.
62. Gahr M, Freudenmann RW, Hiemke C, et al. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol. 2013. [Epub ahead of print].
63. Ernst E. Complementary treatments in rheumatic diseases. Rheum Dis Clin North Am. 2008;34:455-67. (Pubitemid 351970200)
64. Yachoui R, Kolasinski SL. Complementary and alternative medicine for rheumatic diseases. Aging Health. 2012;8:403-12.
65. Terry R, Perry R, Ernst E. An overview of systematic reviews of complementary and alternative medicine for fibromyalgia. Clin Rheumatol. 2012;31:55-66.
66. Laghorst J, Klose P, Musial F, et al. Efficacy of acupuncture in fibromyalgia syndrome -a systematic review with a meta analysis of controlled clinical trials. Rheumatology. 2010;49:778-88.
67. Assefi NP, Sherman KJ, Jacobsen C, et al. A randomized clinical trial of acupuncture compared with sham acupuncture in fibromyalgia. Ann Intern Med. 2005;143:10-9.
68. Williams Jr JW, Gierisch JM, McDuffie J, et al. An overview of complementary and alternative medicine therapies for anxiety and depressive disorders: supplement to efficacy of complementary and alternative medicine therapies for posttraumatic stress disorder. Washington (DC): Department of Veterans Affairs; 2011. Available at http://www.ncbi.nlm.nih.gov/books/NBK82787. Accessed May 2013.
69. Delgado MP, Postigo JML, Rodríguez JM. Terapia cognitiva basada en mindfulness y reducción de los síntomas de ansiedad en personas con fibromialgia. Ansiedad y Estrés. 2012;18:141-54.
70. Vázquez-Rivera S, González-Blanch C, Rodríguez-Moya L, et al. Brief cognitive-behavioral therapy with fibromyalgia patients in routine care. Compr Psychiatry. 2009;50:517-25.
71. • Glombiewski JA, Sawyer AT, Gutermann J, et al. Psychological treatments for fibromyalgia: a meta-analysis. Pain. 2010;151:280-95. An important systematic review and meta-analysis on psychological treatments for fibromyalgia, concluding on the efficacy of structured cognitivecbehavioral psychotherapy.
72. Friedberg F, Williams DA, Collinge W. Lifestyle-oriented non-pharmacological treatments for fibromyalgia: a clinical overview and applications with home-based technologies. J Pain Res. 2012;5:425-35.
73. Hofmann SG, Asnaani A, Vonk IJJ, et al. The efficacy of cognitive behavioral therapy: a review of meta-analysis. Cognit Ther Res. 2012;36:427-40.
74. Okajima I, Komada Y, Inoue Y. A meta-analysis on the treatment effectiveness of cognitive behavioral therapy for primary insomnia. Sleep Biol Rhythms. 2011;9:24-34.
75. Kashikar-Zuck S, Sil S, Lynch-Jordan AM, et al. Changes in pain coping, catastrophizing, and coping efficacy after cognitive-behavioral therapy in children and adolescents with juvenile fibromyalgia. J Pain. 2013;14:492-501.
76. Astin JA, Berman BM, Bausell B, et al. The efficacy of mindfulness meditation plus Qigong movement therapy in the treatment of fibromyalgia: a randomized controlled trial. J Rheumatol. 2003;30:2257-62. (Pubitemid 37221861)
77. Grossman P, Tiefenthaler-Gilmer U, Raysz A, et al. Mindfulness training as an intervention for fibromyalgia: evidence of postintervention and 3-year follow-up benefits in well-being. Psychother Psychosom. 2007;76:226-33. (Pubitemid 46933368)
78. Schmidt S, Grossman P, Schwarzer B, et al. Treating fibromyalgia with mindfulness-based stress reduction: results from a 3-armed randomized controlled trial. Pain. 2011;152:361-9.
79. Fjorback LO. Mindfulness and bodily distress. Dan Med J. 2012;59:B4547.
80. Wicksell RK, Kemani M, Jensen K, et al. Acceptance and commitment therapy for fibromyalgia: a randomized controlled trial. Eur J Pain. 2013;17:599-611.
81. Ang DC, Jensen MP, Steiner JL, et al. Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized-controlled trial. Clin J Pain. 2013. [Epub ahead of print].
82. Botella C, Garcia-Palacios A, Vizcaíno Y, et al. Virtual reality in the treatment of fibromyalgia: a pilot study. Cyber Psychol Behav Soc Netw. 2013;16:215-23.
83. Hayes SC, Strosahl KD, Wilson KG. Acceptance and commitment therapy: an experiential approach to behavior change. New York-London: The Guilford Press; 1999.
84. Kaleth AS, Saha CK, Jensen MP, et al. Moderate-vigorous physical activity improves long-term clinical outcomes without worsening pain in fibromyalgia. Arthritis Care Res. 2013 [Epub ahead of print].
85. Mannerkorpi K, Nordeman L, Cider A, et al. Does moderate-to-high intensity Nordic walking improve functional capacity and pain in fibromyalgia? A prospective randomized controlled trial. Arthritis Res Ther. 2010;12:R189.
86. Ellingson LD, Shields MR, Stegner AJ, et al. Physical activity, sustained sedentary behavior, and pain modulation in women with fibromyalgia. J Pain. 2012;13:195-206.
87. McLoughlin MJ, Stegner AJ, Cook DB. The relationship between physical activity and brain responses to pain in fibromyalgia. J Pain. 2011;12:640-51.
88. Kim CH, Vincent A, Clauw DJ, et al. Association between alcohol consumption and symptom severity and quality of life in patients with fibromyalgia. Arthritis Res Ther. 2013;15:R42.
89. Freidl M, Piralic-Spitzl S, Grohe N, et al. Association between fear of stigma, depressive and anxiety symptoms in patients with somatoform pain disorder. Psychiatr Prax. 2012;39:263-6.